Rosa to Present at 2012 PaSiPhIC Conference

Modeling analysis utilizes AMS/microdosing to improve drug development for infants.

Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that the results from a recent research project will be presented at the 2012 3rd Annual Pacific Coast Statisticians and Pharmacometricians Innovation Conference in San Luis Obispo, CA on June 25, 2012. Dr. Toufigh Gordi will be presenting a poster entitled "Using PK and PhysioPD modeling to clarify drug metabolism". The poster describes the use of AMS microdosing in the development of pharmacokinetic and pharmacodynamics models in pediatric drug development. The presentation will describe the integration of PK/PD and mechanistic physiological models to develop physiological insights and improve drug development. The presentation will highlight how incorporation of PK/PD and physiological modeling can provide insight into mechanisms of patient variability for sensitive populations.

"This project expands our research of physiological, mechanistic models based on microdosing and metabolomic data," said Dr. Mice Reed, Rosa's Vice President. "The use of microdosing data permits development of pharmacokinetic models for endogenous compounds and difficult to measure drug compounds. AMS and microdosing also enables the use of modeling to advance drug development in pediatric and other sensitive populations”.

Rosa informs our customer's most critical decisions - from preclinical through clinical development - with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic (PK/PD) models and Rosa's innovative PhysioPD™ models. With these approaches, Rosa's clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa's staff have unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development and have completed hundreds of engagements with dozens of clients in multiple therapeutic areas. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/antivirals. For more information, visit www.rosaandco.com.
Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.

751 Laurel St., Ste. 127,
San Carlos, CA 94070

This release was published on openPR.